
Medical Student Research Symposium

School of Medicine

March 2020

Antimicrobial Effects of Adjunctive Thymosin beta-4 Therapy in Bacterial Keratitis

Spandana Alluri
fg9173@wayne.edu

Thomas Carion
Wayne State University

Ebrahim Abdul Shukkur
Wayne State University

Gabriel Sosne
Kresge Eye Institute

Elizabeth Berger
Wayne State University

Follow this and additional works at: https://digitalcommons.wayne.edu/som_srs

 Part of the Medicine and Health Sciences Commons

Recommended Citation

Alluri, Spandana; Carion, Thomas; Shukkur, Ebrahim Abdul; Sosne, Gabriel; and Berger, Elizabeth,
"Antimicrobial Effects of Adjunctive Thymosin beta-4 Therapy in Bacterial Keratitis" (2020). *Medical
Student Research Symposium*. 6.

https://digitalcommons.wayne.edu/som_srs/6

This Research Abstract is brought to you for free and open access by the School of Medicine at DigitalCommons@WayneState. It has been accepted for inclusion in Medical Student Research Symposium by an authorized administrator of DigitalCommons@WayneState.

WSU Medical Student Research Symposium Abstract

Purpose: Our lab has been focused on developing thymosin beta-4 (T β 4) as a potential therapeutic for bacterial keratitis, an extremely debilitating ocular infection that is prevalent world wide. T β 4 is a naturally occurring g-actin sequestering peptide, which we have previously shown significantly improves disease outcome in a *P. aeruginosa* (PA)-induced keratitis model when used adjunctively with ciprofloxacin (cipro). Following observations of decreased bacterial load in T β 4 +cipro-treated corneas, this project aims to investigate the synergy between T β 4 and cipro regarding bactericidal effects and antimicrobial peptide (AMP) regulation.

Methods: Minimum inhibitory concentration (MIC) assays were used to quantify the bactericidal activity of ciprofloxacin, T β 4, and a combination of cipro with T β 4 to evaluate synergy. Micro serial dilutions were carried out using 96 well plates and concentrations of PA prepared for 10⁵ and 10⁶ CFU/mL inoculum. Additionally, we began to further elucidate the mechanism behind T β 4 mediated effects by assessing the impact of T β 4 on the activation of AMP pathways. Human corneal epithelial cells (HUCs) were stimulated with LPS (25 μ g/mL) for 6 and 24 hours. Experimental groups included: CTRL, T β 4, cipro, and T β 4 +cipro. Additionally, mRNA and protein levels of AMPs, including LL-37, S100A8, hBD-3, keratin6A, and TLR-4 were also assessed.

Results: Though we expected to see a further decrease in MIC for adjunct T β 4 therapy in comparison with cipro alone, the two groups exhibited similar results without a significant difference in MIC. Surprisingly however, the MIC assay showed very little bacterial growth with ciprofloxacin alone, even at significantly low concentrations. Unexpectedly, T β 4 alone did not show significant bactericidal activity. Regarding AMP expression, RT-PCR results revealed upregulation of a number of AMPs in response to T β 4 stimulation at 6 hrs, as well as further upregulation in combo groups at 24 hrs, indicating a possible synergistic effect. This trend has been similarly observed with select lipoxygenase enzymes and SPM receptors.

Conclusion: We believe that the results from our experiments help provide evidence by which Tb4 influences the antimicrobial effects observed in the bacterial keratitis model. More importantly, suggestions of a synergistic effect between Tb4 and cipro at the gene level, as well as findings of an extremely low MIC for ciprofloxacin may allow for lower concentrations of antibiotic to be used in the clinical setting. This would not only decrease the risk for potential side effects/toxicity issues related to the use of antibiotics, but potentially reduce antimicrobial resistance.